What Are the Symptoms of Wegovy — and What Do They Mean for You?

The GI symptoms most people encounter, and why they happen at that point

Most of Wegovy's side-effect profile flows from one central mechanism: semaglutide slows gastric emptying, so food stays in the stomach longer. That is partly what reduces appetite, but it also means the gut has to adapt. Nausea is the standout complaint, reported by roughly four in ten people in the STEP 1 trial; vomiting, diarrhoea and constipation each affect a meaningful minority. Indigestion, reflux, burping and bloating are also common enough to appear regularly in the NHS medicines guidance on semaglutide.

The timing follows a predictable arc. Symptoms are worst in the first few days after a new dose begins, particularly in the early weeks of the titration schedule. By the time the body has adjusted (usually within one to two weeks) they tend to become noticeably milder. Some people describe their nausea as negligible by month two; others find it persists longer. That variability is real, and if you are finding GI symptoms hard to manage it is worth telling your prescriber rather than pushing through.

Practical adjustments that consistently help: eating smaller portions, slowing down at meals, avoiding very fatty or heavily spiced food around injection day, and staying well hydrated. These are not substitutes for clinical advice, but they are the things that the question "what can I actually do about this?" usually leads to. Headache, fatigue and dizziness are also reported, again, typically mild and front-loaded into dose increases. Injection-site reactions (redness, bruising, itching) occur occasionally; rotating the site each week reduces them.

Symptoms that need urgent medical attention, not a wait-and-see approach

Most Wegovy side effects are self-limiting and manageable. A smaller set are not, and it is important to know them before you start rather than when you are already unwell. The clearest one is acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update specifically flagging this risk for GLP-1 receptor agonists: the symptom to act on is severe, persistent stomach pain (often spreading to the back, sometimes accompanied by vomiting) that does not ease off. If that happens, stop waiting and seek urgent medical help. You can report suspected side effects at the MHRA's Yellow Card scheme, which also helps build the post-market safety picture for medicines like Wegovy.

Gallbladder problems are a related concern. Rapid weight loss and altered gut motility can shift the conditions under which gallstones form; symptoms such as upper-right abdominal pain, especially after eating, should be assessed by a doctor. Signs of a significant allergic reaction (pronounced swelling, breathing difficulty, severe rash) need emergency attention. And anyone with a known history of medullary thyroid carcinoma or MEN2 (multiple endocrine neoplasia type 2) should not be taking semaglutide in the first place; this is part of what the prescriber screening is for.

Kidney function can be affected indirectly: severe vomiting or diarrhoea leading to dehydration can cause acute kidney injury in vulnerable people. Keeping fluid intake up is not just comfort advice. Eyesight changes in people with diabetic retinopathy and low mood or self-harm thoughts are also flagged in the product information as things to report to a clinician without delay.

Deciding whether the symptoms you are experiencing change your path forward

This is the decision most people are really making when they search this question. You are either considering Wegovy and want to know what to expect, or you are already taking it and trying to work out whether what you are feeling is normal or a reason to pause. Both are legitimate. And if the honest answer is that you are feeling put off by what you have read about the side effects, that is reasonable too. GI disruption in the first few weeks is genuinely unpleasant for some people.

The clinical picture, though, is that the majority of people in trials did not stop treatment because of side effects, and trial populations tend to be closely monitored. In real-world practice, the titration schedule (starting at a low dose and working up slowly over months) exists precisely to keep side effects manageable. The worst nausea most people describe is at 0.25mg and 0.5mg; by the time 2.4mg maintenance is reached, the body has usually had several months to adjust. For context on how Wegovy's costs and structure fit the wider picture, our Wegovy pricing page sets out what private treatment involves.

If you are already on Wegovy and noticing symptoms that concern you, the right next step is your prescribing team. Our prescribers are available for aftercare seven days a week. For those still deciding, understanding what symptoms look like on day one of semaglutide versus several weeks in can help set realistic expectations. What stopping looks like is a separate question, the symptoms of stopping Wegovy are different from those of taking it, and worth reading about before making any changes without clinical input.

Symptoms that are less discussed but worth knowing about

A few categories come up less often in headlines but matter in practice. Hair thinning is reported anecdotally and documented in some post-market data; it appears to relate more to rapid calorie reduction and the physical stress of significant weight change than to semaglutide directly, and typically reverses as weight stabilises. Mentioning it to a prescriber is worthwhile if it is significant.

There is a growing body of patient-reported experience around what some call "Wegovy face", visible changes to facial appearance with rapid weight loss. This is not a side effect of the medicine itself but a consequence of fat redistribution; it is documented with weight loss generally, not semaglutide specifically. Similarly, muscle loss is a risk when losing weight quickly, which is why the guidance accompanying GLP-1 treatment consistently emphasises adequate protein and resistance exercise alongside treatment.

UTI-type symptoms occasionally come up in patient questions. The evidence linking semaglutide directly to urinary tract infections is limited, but the topic comes up enough that our page on whether Wegovy causes UTI symptoms addresses it specifically. If you want a fuller look at what living with the treatment feels like week to week, the experience of taking Wegovy over time covers a broader day-to-day picture. More background on semaglutide as a medicine is on our semaglutide overview, and the Wegovy page covers eligibility and how the UK treatment pathway works. Wegovy is a prescription-only medicine and a clinician decides whether it is appropriate for you; if you are ready to have that conversation, checking your eligibility with our prescribers is the place to start.